TermGallery
English
English
Spanish
Catalan
Portuguese
Russian
EN
English
Español
Català
Português
Русский
1
The pathophysiologic continuum of
non-alcoholic
fatty
liver disease begins with steatosis.
2
The incidence of
non-alcoholic
fatty
liver disease (NAFLD) increases with age.
3
These beneficial effects of metformin implicate a role for metformin in managing
non-alcoholic
fatty
liver disease.
4
Identifying modifiable risk factors for
non-alcoholic
fatty
liver disease development is essential to design effective prevention programmes.
5
Background & aims: In
non-alcoholic
fatty
liver disease, presence of fibrosis is predictive of long-term liver-related complications.
6
Conclusions: Decreased myeloid ARNT may play a role in the conversion from
non-alcoholic
fatty
liver to steatohepatitis.
7
The result showed that non-alcoholic fatty liver disease activity score was significantly decreased in all types of treatment.
8
We tested whether 25-year patterns of body mass index change are associated with midlife
non-alcoholic
fatty
liver disease.
9
Recent studies have shown that macrophages are involved in
non-alcoholic
fatty
liver disease, liver fibrosis, and hepatocellular carcinoma.
10
Currently, there are no reliable and non-invasive means of quantifying fibrosis in those with
non-alcoholic
fatty
liver disease.
11
Objective: Experimental and observational studies suggest a role for uric acid in
non-alcoholic
fatty
liver disease (NAFLD).
12
To understand the mechanisms implicated in development of NASH, animal models of
non-alcoholic
fatty
liver disease have been generated.
13
Recent studies have shown that
non-alcoholic
fatty
liver disease (NAFLD) is a critical pathway to metabolic syndrome.
14
Background: There are few studies investigating the natural course of
non-alcoholic
fatty
liver disease (NAFLD) in the community.
15
Background: The prevalence of
non-alcoholic
fatty
liver disease is increasing worldwide and an effective and safe pharmacological treatment is needed.
16
Then, a color FF map was generated with the corrected MRI-FF based on the
non-alcoholic
fatty
liver disease activity score.
non-alcoholic
fatty
non-alcoholic